Vortioxetine to Prevent Return of Symptoms in Children With Depression
A Double-blind, Randomized, Placebo-controlled, Multicentre, Relapse-prevention Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder
Sponsor: H. Lundbeck A/S
Terminated
The study was terminated based on new efficacy data from another study.
Listed as NCT05014919, this PHASE3 trial focuses on Depression and remains terminated or withdrawn. Sponsored by H. Lundbeck A/S, it has been updated 12 times since 2021, reflecting substantial change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Feb 2023 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2022 — Feb 2023 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
▶ Show 7 earlier versions
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE3
-
Mar 2022 — May 2022 [monthly]
Recruiting PHASE3
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE3
-
Dec 2021 — Feb 2022 [monthly]
Recruiting PHASE3
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE3
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE3
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE3
First recorded
Aug 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- H. Lundbeck A/S
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Atlanta, United States , Barranquilla, Colombia , Bogotá, Colombia , Culiacan de Rosales, Mexico , Engel's, Russia , Kielce, Poland , Liepāja, Latvia , Long Beach, United States , Monterrey, Mexico , Odesa, Ukraine and 6 more locations